Diabetes Mellitus, Type 2 Clinical Trial
Official title:
Relationship Between HbA1c, Fasting Plasma Glucose, Post-prandial Glucose and Other Measures of Glycemic Control in Malaysian Type 2 Diabetes Mellitus Patients
This study aims to evaluate relative contributions of fasting plasma glucose and
postprandial glucose at various HbA1c levels using 6-day CGM. Evaluation of the relationship
between HbA1c, CGM, serum fructosamine and eAG, will also be looked into.
HYPOTHESES:
1. Fasting hyperglycaemia is the main contributor in Malaysian T2DM patients with poor
glycaemic control (high HbA1c), postprandial hyperglycaemia plays a more important role
with lower HbA1c levels.
2. There is good correlation between HbA1c, CGM, serum fructosamine and eAG in Malaysian
patients.
Glycated haemoglobin (HbA1c) is formed via a non-enzymatic glycation pathway by the exposure
of haemoglobin to plasma glucose. The HbA1c assay is widely used to assess glycaemic control
in diabetes mellitus (DM) over a 60 to 90 day period and has been shown to correlate with
the development of complications in both Type 1 (T1DM) and Type 2 diabetes mellitus (T2DM).
(A) HbA1c, Fasting Plasma Glucose and Post-prandial Glucose
Several studies have looked at the relationship between fasting glucose, post-prandial
glucose and HbA1c, yielding conflicting results.
In 2001, one study examined the relationships between plasma glucose and HbA1c in 371 T2DM
patients who were on lifestyle modification or oral antidiabetic drugs (OADs). These
patients performed self monitoring of blood glucose (SMBG) 5 to 6 times per day (fasting,
pre-meal and 2 hours post-prandial). In this study HbA1c had better correlation with
pre-prandial glucose rather than postprandial hyperglycaemia.
A landmark study was carried out in 2003 using one-day, 4-point, SMBG profiles in 290 T2DM
patients who were on oral anti-diabetic drugs (OAD) but not on insulin. This study suggested
that in patients with HbA1c < 8.5%, post-prandial hyperglycaemia was the main contributor to
excessive glucose levels. Conversely, in patients with HbA1c levels ≥ 8.5%, fasting
hyperglycaemia predominated. This pattern has been proposed to reflect the natural
progression of T2DM, with post-prandial hyperglycaemia occurring earlier in the course of
T2DM and fasting hyperglycaemia gradually predominating with progressive β-cell failure.
This concept was challenged later, where 7-point SMBG profiles at baseline and after 24
weeks were performed in 1699 patients with T2DM (on OAD or insulin therapy) with HbA1c ˃ 7%.
It found that fasting hyperglycaemia was the main contributor to overall hyperglycaemia
(76-80%) from the lowest to highest HbA1c levels.
Another similar study was carried out in Taiwan in 2010 (Asian descent), with several key
differences. This is important as Asian T2DM patients have been shown to have a
predominantly insulin secretory defect as opposed to the insulin resistance which typifies
T2DM in Caucasians. Different ethnic populations have also been shown to glycate haemoglobin
at different rates. HbA1c is consistently higher in African Americans compared to
non-Hispanic White, no matter if normal glucose tolerance (by 0.13-0.21%), pre-diabetes (by
0.26-0.30%) or diabetes (by 0.47%). Another key difference in the taiwanese study was the
use of continuous glucose monitoring (CGM) over a 3 day period in 121 T2DM patients treated
with OAD, which provided a far greater number of measured glucose values compared to SMBG.
It found that post-prandial hyperglycaemia contributed significantly (80%) to overall
hyperglycaemia when HbA1c was < 7%. At levels of HbA1c > 7%, the study reported that both
fasting and post-prandial glucose levels made equal contributions to the overall glycaemic
status.
(B) HbA1c, serum fructosamine and estimated average glucose (eAG)
Although HbA1c is regarded as the gold standard in the assessment of overall glycaemic
status in diabetes mellitus, there are several limitations to its use. Factors affecting
erythrocyte turnover, such as haemoglobinopathies (which are more prevalent in Asians),
chronic renal failure, recent blood transfusion and erythropoietin therapy may render HbA1c
unsuitable for assessing glycaemic status. In such instances, other methods for assessing
glycaemic control may be used.
Fructosamine is formed when plasma glucose reacts with protein. Serum fructosamine levels
have been used to indicate average glucose levels over a 2 to 3 week period. The correlation
between serum fructosamine and HbA1c levels has been described in Caucasians but not in an
Asian population12. It was reported that there was discordance between HbA1c and
fructosamine, especially in the presence of nephropathy.
SMBG and CGM are alternatives to HbA1c in assessing chronic glycaemia. The A1c-derived
Average Glucose (ADAG) study looked at 700 individuals (300 T1DM, 300 T2DM and 100 healthy
individuals). HbA1c, 8-point SMBG and 48-hour CGM were assessed monthly over a 4 month
period. Glucose levels accrued from SMBG and CGM were used to calculate estimated average
glucose levels (eAG).The ADAG study identified a linear relationship between HbA1c and eAG
over the preceding 8-12 weeks for both T1DM and T2DM patients with normal erythrocyte
lifespan. One of the limitations of the ADAG study was the under-representation of Asians
subjects.
By performing our study, we aim to evaluate the glycaemic profiles of T2DM patients over a
wide spectrum of HbA1c, by using 6 day CGM, from Asian perspectives. We also hope to
establish positive correlation among HbA1c, serum fructosamine, estimated average glucose
and CGM in this group of population.
;
Observational Model: Case-Only, Time Perspective: Cross-Sectional
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT05666479 -
CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
|
||
| Completed |
NCT05647083 -
The Effect of Massage on Diabetic Parameters
|
N/A | |
| Active, not recruiting |
NCT05661799 -
Persistence of Physical Activity in People With Type 2 Diabetes Over Time.
|
N/A | |
| Completed |
NCT03686722 -
Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin
|
Phase 1 | |
| Completed |
NCT02836704 -
Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose)
|
Phase 4 | |
| Completed |
NCT01819129 -
Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes
|
Phase 3 | |
| Completed |
NCT04562714 -
Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy
|
N/A | |
| Completed |
NCT02009488 -
Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)
|
Phase 1 | |
| Completed |
NCT05896319 -
Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2
|
N/A | |
| Recruiting |
NCT05598203 -
Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes
|
N/A | |
| Completed |
NCT05046873 -
A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People
|
Phase 1 | |
| Completed |
NCT04030091 -
Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus
|
Phase 4 | |
| Terminated |
NCT04090242 -
Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes
|
N/A | |
| Completed |
NCT03620357 -
Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D)
|
N/A | |
| Completed |
NCT03604224 -
A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
|
||
| Completed |
NCT01696266 -
An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
|
||
| Completed |
NCT03620890 -
Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy
|
Phase 4 | |
| Withdrawn |
NCT05473286 -
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
|
||
| Not yet recruiting |
NCT05029804 -
Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes
|
N/A | |
| Completed |
NCT04531631 -
Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes
|
Phase 2 |